Amplifon S.p.A. stock (IT0004056880): Hearing aid leader navigates global expansion

Amplifon S.p.A., a top player in hearing care services, continues to grow its network amid rising demand for audiology solutions worldwide. Recent financials show steady revenue gains in key markets.

Amplifon S.p.A. reported solid performance in its latest financial update, with revenue growth driven by expansion in Europe and North America. The company, which operates over 5,000 stores globally, focuses on hearing aid fittings and related services. According to its investor relations page as of 05/11/2026, Amplifon serves millions of customers annually through a mix of retail clinics and online consultations.

As of: 11.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Amplifon S.p.A.
• Sector/industry: Healthcare / Hearing care services
• Headquarters/country: Milan, Italy
• Core markets: Europe, North America, Asia-Pacific
• Key revenue drivers: Hearing aid sales and services
• Home exchange/listing venue: Borsa Italiana (AMP.MI)
• Trading currency: EUR

Amplifon S.p.A.: core business model

Amplifon S.p.A. specializes in hearing care, providing diagnostic services, hearing aids, and maintenance through a vast network of clinics. Founded in 1950, the company has grown into one of the world's largest hearing service providers, with a presence in 26 countries. Its model combines retail storefronts with digital tools for customer engagement, emphasizing personalized audiology solutions.

The business relies on partnerships with leading hearing aid manufacturers, allowing Amplifon to offer a wide range of devices. Revenue is primarily from service fees and device sales, with recurring income from follow-up visits and accessories. This integrated approach positions Amplifon well in an aging global population driving demand.

Main revenue and product drivers for Amplifon S.p.A.

Hearing aid sales account for the bulk of revenue, supplemented by audiology services like testing and rehabilitation. In its 2024 annual report published March 2025, Amplifon posted group revenue of €2.3 billion for the year ended December 31, 2024, up 8% year-over-year, per company filings as of 03/2025. North America contributed 25% of sales, highlighting US market exposure.

Key products include premium digital hearing aids with AI features for noise reduction and connectivity. Accessories like batteries and remote controls add steady streams. Growth in emerging markets like Brazil and India supports long-term expansion.

Industry trends and competitive position

The global hearing aid market is projected to reach $10 billion by 2028, fueled by demographics and over-the-counter (OTC) device approvals in the US. Amplifon benefits from this shift, with its clinic network offering expert fittings alongside OTC options. Competitors include Sonova and Demant, but Amplifon's service focus differentiates it.

Technological advances, such as Bluetooth-enabled aids, align with Amplifon's portfolio. The company's 2025 first-quarter results, released May 2025, showed 10% like-for-like growth, underscoring resilience amid economic pressures.

Why Amplifon S.p.A. matters for US investors

Amplifon generates significant revenue from North America, where hearing loss affects 30 million adults. Its US operations, under brands like Miracle-Ear, tap into a $4 billion market. Listing on Borsa Italiana provides US investors access via ADRs or direct trading, with exposure to healthcare tailwinds like Medicare expansions.

Rising awareness and insurance coverage in the US bolster Amplifon's growth. The stock's performance ties to demographic trends relevant to American portfolios seeking defensive healthcare plays.

Conclusion

Amplifon S.p.A. maintains a strong position in the hearing care sector, supported by global expansion and demographic trends. Recent financials indicate consistent growth, particularly in key markets including the US. Investors track its ability to navigate regulatory changes and technological shifts in audiology.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.